ArticleCell reports2026
CGRP signaling links tumor-associated pain to immune evasion in oral squamous cell carcinoma.
Article in Cell reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Radiotherapy-Associated Pain in Head and Neck Cancer: From Clinical Burden to Neuroimmune Modulator.Journal of clinical medicine · 2026Review
- The Potential and Prospects of Marine Drugs in Intervening Nerve-Tumor Crosstalk.Marine drugs · 2026Review
- Calcitonin Gene-Related Peptide (CGRP): Biology, Signaling, Pathophysiological Roles, and Therapeutic Applications.International journal of molecular sciences · 2026Review
- CGRP: the immune system's double agent - context-dependent roles in inflammation, resolution and cancer.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Peripheral sensory nerves are thought to play a role in solid tumor growth, particularly in oral squamous cell carcinoma (OSCC); however, the link between pain and immunosuppression remains unresolved. Here, we find an inverse relationship between OSCC-associated pain by way of calcitonin gene-related peptide (CGRP)-expressing nerves and tumor-associated immunity in patients with OSCC. Bulk RNA sequencing of tumor-innervating sensory neurons from syngeneic mouse models of OSCC shows differential regulation of genes associated with excitability, neurotransmission, and axonal sprouting. Using a gain-of-function approach by persistently stimulating peptidergic afferents, we show that sensory neurons support the growth of oral tongue tumors and limit the activation of an effective anti-tumor immune response via efferent CGRP release. Loss-of-function approaches, such as local ablation of nociceptive nerves or systemic CGRP receptor antagonism, slow tumor growth and improve anti-tumor immunity. Targeting CGRP may serve as a potential therapeutic strategy in OSCC to reduce pain and improve therapeutic response.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.